<DOC>
	<DOCNO>NCT01944683</DOCNO>
	<brief_summary>The study examine midazolam pharmacokinetics follow single dose administration 3 plan dose level GGF2 .</brief_summary>
	<brief_title>A Double-Blind Pharmacokinetic Interaction Study Evaluating Effect Single IV Infusion GGF2 Placebo Midazolam Pharmacokinetics Patients With Heart Failure</brief_title>
	<detailed_description>This drug-drug interaction ( DDI ) study evaluate potential effect intravenously administer GGF2 elimination kinetics midazolam .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>If female , must least 2 year postmenopausal bilateral oophorectomy , hysterectomy document sterility If male , must document sterility ( verbal report previous vasectomy ) , nonsterile , must agree use barrier contraception entire duration trial 3 month last dose investigational product . Must also agree donate sperm study 3 month last dose investigational product Stable coronary disease without unstable angina acute coronary syndrome last 6 month All cardiac medication , specifically betablockers , reninangiotensin system inhibitor , aldosterone antagonist , hydralazine nitrate stable dose ( least 4 week ) prior Day 1 Any previous exposure GGF2 neuregulins Initiation change prescription medication within 2 week prior Day 1 , and/or concomitant medication regimen expect change course study Known allergic reaction midazolam , component midazolam syrup ( include cherry flavoring ) , component GGF2 diluent Known specific hepatic disease ; total bilirubin &gt; 2 mg/dL , AST &gt; 100 IU History hepatic impairment ( hepatitis B C ) Type I Diabetes Documented stroke transient ischemic attack ( TIA ) within 2 month study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>